Infant botulism in the age of botulism immune globulin.
Infant botulism causes acute bulbar dysfunction, weakness, and respiratory failure in infants living in endemic regions of the United States. Until Food and Drug Administration approval of botulism immune globulin (BIG) in October 2003, management of infant botulism had changed little since the 1970s. Currently, IV therapy with BIG is advised to shorten the duration and diminish the potential complications of the disorder. This review describes two decades of experience with infant botulism and provides a contemporary perspective on the role and benefit of BIG.
Thompson
J A
JA
Division of Pediatric Neurology, Department of Pediatrics, The University of Utah, Primary Children's Medical Center, Salt Lake City, UT, USA. joel.thompson@hsc.utah.edu
Filloux
F M
FM
Van Orman
C B
CB
Swoboda
K
K
Peterson
P
P
Firth
S D
SD
Bale
J F
JF
D001906:Botulism / Q000188:drug therapy* / Q000453:epidemiology* / Q000503:physiopathology; D004781:Environmental Exposure / Q000706:statistics & numerical data; D005248:Feeding Methods / Q000706:statistics & numerical data; D005260:Female; D041981:Gastrointestinal Tract / Q000382:microbiology / Q000503:physiopathology; D006760:Hospitalization / Q000706:statistics & numerical data; D006801:Humans; D007136:Immunoglobulins / Q000627:therapeutic use*; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use; D007223:Infant; D007902:Length of Stay; D008297:Male; D014481:United States / Q000453:epidemiology
D007136:Immunoglobulins; D016756:Immunoglobulins, Intravenous; C068584:botulism immune globulin